key: cord-1006706-iqe8dx4d
authors: Schirmer, P; Lucero-Obusan, C; Sharma, A; Sohoni, P; Oda, G; Holodniy, M
title: Respiratory Co-infections with COVID-19 in the Veterans Health Administration, 2020
date: 2021-01-20
journal: Diagn Microbiol Infect Dis
DOI: 10.1016/j.diagmicrobio.2021.115312
sha: 5209bc2e523e31bcf3c45b56ee507ac687c12710
doc_id: 1006706
cord_uid: iqe8dx4d

Reporting of COVID-19 co-infections with other respiratory pathogens has varied. We evaluated 825,280 molecular/viral culture respiratory assays within the Veterans Health Administration from 9/29/2019-5/31/2020. SARS-CoV-2 was detected in 10,222 of 174,746 (5.8%) individuals. 30,063 (17.2%) of 174,746 individuals tested for SARS-CoV-2 had additional respiratory pathogen testing; co-infection was identified in 56 of 3,757 (1.5%) individuals positive for SARS-CoV-2. Among those negative for SARS-CoV-2, 1,022 of 26,306 (3.9%) were positive for at least one respiratory pathogen. Compared to COVID-19 mono-infection, individuals with COVID-19 co-infection had lower odds of being female. Compared to non-COVID-19 respiratory pathogen infection, individuals with COVID-19 co-infection had lower odds of being female, were hospitalized more frequently, had higher odds of death, and were younger at death. Our findings suggest COVID-19 co-infections were rare; however, not all COVID-19 patients were concurrently tested for other respiratory pathogens and seasonal decreases in other respiratory pathogens were occurring as COVID-19 emerged.

. Three individuals were identified with more than 1 147 other respiratory pathogen (2 with coronavirus NL63 and adenovirus and 1 with a coronavirus NL63 and 148 rhinovirus/enterovirus). No COVID-19 co-infections with Bordetella pertussis/parapertussis or 149

Mycoplasma pneumoniae were identified. Table 2 summarizes characteristics of COVID-19 co-infected,  150 COVID-19 mono-infected, and non-COVID-19 respiratory pathogen infected individuals and Table 3 The COVID-19 co-infected group had fewer females compared to both the COVID-19 mono-infected and 158 the non-COVID-19 respiratory pathogen infected group (p=0.03, OR 0.2, 95% CI 0.008-0. 8 Less has been reported on COVID-19 co-infections compared to non-COVID-19 respiratory pathogen 208 infected individuals during the pandemic. In our study, when COVID-19 co-infected were compared to 209 non-COVID-19 respiratory pathogen infected, those individuals were less likely to be female, but were 210 more likely to be Black/African American, had more hospitalizations, had a higher odds of death, and 211

were younger at the time of death. Xie et al also noted that COVID-19 infected patients (without COVID-212 19 co-infection) were more likely to have extrapulmonary organ dysfunction, death, admission to an ICU 213 and longer hospital length of stay compared to seasonal influenza infected patients [22] . Further 214 analysis of factors contributing to these findings are warranted. 215

Our study has limitations. Detection of COVID-19 co-infections in our cohort may have been limited 217 since only 17.2% of patients with SARS-CoV-2 testing were also tested for other respiratory pathogens 218 during the study period making the 1.5% found with COVID-19 co-infection likely an underestimation of 219 COVID-19 co-infections. We also did not analyze bacterial or fungal co-infections that were not part of a 220 standard respiratory panel, whether identified infections were healthcare-associated or what 221 treatments patients received. As the onset of the COVID-19 pandemic began at the tail end of 2019-20 222 influenza season, other respiratory pathogen positivity was decreasing and therefore identification of 223 other non-COVID respiratory pathogens was likely lower than it would have been earlier in the winter. 224

In addition, SARS-CoV-2 testing was both policy dependent and at the discretion of the provider. Testing 225 was also initially reserved for those with symptoms who presented to VHA healthcare facilities, which 226 11 could have limited detection of asymptomatic or more mild cases of COVID-19 (or other non-COVID 227 respiratory pathogens) that didn't seek medical attention or avoided in-person visits to VA medical 228 centers for evaluation. There was also widespread reagent and consumable shortages, which could 229 have affected SARS-CoV-2 and respiratory pathogen testing availability. The number of tests performed 230 varied across respiratory pathogens as there was no standardized test for respiratory pathogens in use 231 across all VHA facilities. Some facilities performed testing in-house while others sent specimens to 232 commercial laboratories with multiple respiratory pathogen panels available (Supplemental Table 1 This manuscript or a very similar manuscript has not been published, nor is under consideration by any other journal.

COVID-19) Cases in the

Epidemiological and clinical characteristics of 99 cases of 2019 novel 273 coronavirus pneumonia in Wuhan, China: a descriptive study

Overview of Testing for SARS-CoV-2

Only more updated link is currently available

The Importance of Novel 278

Coronavirus Disease (COVID-19) and Coinfection with Other Respiratory Pathogens in the Current 279

Co-infection with respiratory pathogens among COVID-2019 cases

Influenza and COVID-19 coinfection: Report of six cases and review 283 of the literature

Co-infection in SARS-CoV-2 infected Patients: Were Are 285

Influenza Virus and Rhino/Enterovirus? J of Med Virol

Co-288 infections of SARS-CoV-2 with multiple common respiratory pathogens in infected patients

Co-infection with SARS-CoV-2 and Human Metapneumovirus

The clinical characteristics of pneumonia patients co-infected with 293 2019 noval coronavirus and influenza virus in Wuhan

COVID-19 and mycoplasma pneumoniae 296 coinfection

SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia, China. Emerg Infect Dis

Original Publication Date: 3/11/2020

SARS-CoV-2 and influenza virus co-infection

Co-infection with SARS-CoV-2 and 307 influenza A virus. IDCases

Co-infection of Coronavirus Disease 2019 and Influenza A: A 309